Literature DB >> 8100281

Outpatient benzodiazepine detoxification procedure for methadone patients.

D R McDuff1, R P Schwartz, A Tommasello, S Tiegel, T Donovan, J L Johnson.   

Abstract

Benzodiazepines are used by a substantial minority of opioid addicts on methadone maintenance. Alprazolam, now the most widely prescribed benzodiazepine in the United States, appears to have supplanted diazepam as the benzodiazepine drug of choice in this population. Its greater addiction liability, shorter half-life, and more intense withdrawal symptoms make addiction to alprazolam more likely and its management in methadone patients more complicated. This article describes a slow outpatient tapered reduction procedure that was utilized to detoxify benzodiazepine dependent methadone patients seen over a two-year period. The reduction procedure was offered to 22 opioid addicts on methadone maintenance who were regularly ingesting low to moderate amounts of benzodiazepines, primarily alprazolam. Of the 22 patients, 4 patients refused outpatient detoxification, and 18 were started on a reduction procedure. Twelve patients completed the detoxification procedure which averaged 7.8 weeks. Comparisons are made between completers and non-completers and essential design features of the procedure are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100281     DOI: 10.1016/0740-5472(93)90078-g

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  3 in total

1.  Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients.

Authors:  John J Mariani; Robert J Malcolm; Agnieszka K Mamczur; Jean C Choi; Ronald Brady; Edward Nunes; Frances R Levin
Journal:  Am J Drug Alcohol Abuse       Date:  2016-03-10       Impact factor: 3.829

Review 2.  Polydrug abuse: a review of opioid and benzodiazepine combination use.

Authors:  Jermaine D Jones; Shanthi Mogali; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-08-02       Impact factor: 4.492

3.  Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?

Authors:  K Blum; M Gold; E J Modestino; D Baron; B Boyett; D Siwicki; L Lott; A Podesta; A K Roy; M Hauser; B W Downs; R D Badgaiyan
Journal:  J Syst Integr Neurosci       Date:  2018-05-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.